Skip to content Skip to footer
Subscribe Now
NEWS

Neurotech Pharmaceuticals Reports the US FDA Approval for Encelto to treat Macular Telangiectasia Type 2

Shots:

  • The US FDA has approved Encelto (revakinagene taroretcel-lwey) to treat macular telangiectasia type 2 (MacTel); commercially available in the US by Jun 2025
  • Approval was based on P-III trial data demonstrating reduced macular photoreceptor loss for ~24mos. post-implantation
  • Encelto (intravitreal implant) utilizes an encapsulated cell therapy tech to continuously deliver ciliary neurotrophic factor (CNTF) doses to the retina for slowing disease progression in MacTel pts

Ref: Businesswire | Image: Neurotech Pharmaceuticals

Related News:- ARS Pharmaceuticals’ neffy 1mg Secures the US FDA’s Approval to Treat Type I Allergic Reactions in Children

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Tags:

You May Also Like

Celltrion
May 23, 2024
The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)
Arrowhead Pharmaceuticals
4 days ago
Arrowhead Pharmaceuticals Receives the NMPA Approval for Redemplo (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)
Herantis Pharma
May 14, 2025
Herantis Pharma Reports First Patient Dosing in P-Ib Trial of HER-096 for Parkinson’s Disease

Contact US

 Second Floor, H-65, Sector 63 Noida, Uttar Pradesh, INDIA – 201301

 +1 (289) 778-4900

 connect@pharmashots.com

OUR INFORMATION

About Us

Announcements

FAQ

Privacy Policy

Terms & Conditions

Grievance Redressal

FOLLOW US

Contact US

Copyright © 2018 – 2026 PharmaShots – All Rights Reserved.

We chose the name PharmaShots to reflect our mission of delivering concise, high-impact, and actionable insights — or “shots” — for decision-makers across the biopharma and healthcare ecosystem. Each story, update, or insight is designed to be sharp, focused, and easy to consume, helping readers quickly grasp what truly matters in a fast-moving industry.

PharmaShots operates at the intersection of media, insights, and brand visibility for the life sciences industry. Our core offerings include:

  • Curated biopharma and healthcare news & analysis

  • Deep-dive insight reports, lists, and industry rankings

  • Sponsored content and brand storytelling

  • Digital marketing and content distribution

  • Event and congress media partnerships

  • Interviews, viewpoints, and expert-led features

  • Newsletter sponsorships and targeted outreach

All services are designed to help companies communicate value, thought leadership, and innovation to the right audience.

PharmaShots content is created and curated by experienced healthcare writers, editors, analysts, and subject-matter contributors with strong backgrounds in biopharma, life sciences, healthcare research, and business insights.

Our editorial process focuses on clarity, accuracy, and relevance, ensuring every piece delivers insight rather than noise.

Our readers come from across the global healthcare and life sciences ecosystem, including:

  • Healthcare decision-makers

  • Biopharma and biotech professionals

  • Medtech and diagnostics leaders

  • Researchers and clinicians

  • Strategy, business development, and competitive intelligence teams

  • Investors and consultants

  • Digital health and AI innovators

  • Marketing, communications, and market access professionals

They rely on PharmaShots to stay informed, make decisions faster, and spot emerging trends early.

PharmaShots is updated daily with fresh content across news, insights, interviews, and special reports. Updates may occur daily or multiple times per week depending on industry activity, major announcements, and ongoing coverage themes.

Readers can stay connected with PharmaShots through multiple channels:

  • Subscribe to our email newsletter for curated weekly updates

  • Follow PharmaShots on LinkedIn and other social platforms

  • Visit the website regularly for new stories and reports

  • Engage with special editions, rankings, and event coverage

These channels ensure you never miss key developments shaping biopharma and healthcare.

You can reach out to PharmaShots through our website’s contact page or via email at connect@pharmashots.com for inquiries, collaborations, or feedback. Visit pharmashots.com for more details

For general inquiries, partnerships, media collaborations, or support, you can reach us at:

Email: connect@pharmashots.com

Address: PharmaShots Media Private Limited

Second Floor, H-65, Sector 63
Noida, Uttar Pradesh, India – 201301

Phone: India: +91 9582 193319 

US/Canada: +1 (289) 778-4900